Dominari (DOMH) Competitors

Minerva Neurosciences (NASDAQ:NERV) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, community ranking, risk, profitability, valuation and earnings.

Does the media refer more to NERV or DOMH?

In the previous week, Dominari had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 2 mentions for Dominari and 1 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.80 beat Dominari's score of 0.67 indicating that Dominari is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dominari	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of NERV or DOMH?

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 6.4% of Minerva Neurosciences shares are held by insiders. Comparatively, 9.7% of Dominari shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has higher earnings and valuation, NERV or DOMH?

Dominari has higher revenue and earnings than Minerva Neurosciences. Dominari is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$30M	-$4.65	-0.54
Dominari	$2.04M	8.14	-$22.88M	-$4.44	-0.63

Is NERV or DOMH more profitable?

Dominari's return on equity of 0.00% beat Minerva Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-50.27%
Dominari	N/A	-37.80%	-34.85%

Which has more risk & volatility, NERV or DOMH?

Minerva Neurosciences has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, Dominari has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.

Do analysts rate NERV or DOMH?

Minerva Neurosciences presently has a consensus target price of $11.00, indicating a potential upside of 340.00%. Given Dominari's higher possible upside, research analysts plainly believe Minerva Neurosciences is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dominari	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Does the MarketBeat Community favor NERV or DOMH?

Minerva Neurosciences received 347 more outperform votes than Dominari when rated by MarketBeat users.

Company	Underperform	Outperform
Minerva Neurosciences	Outperform Votes 347 60.98%	Underperform Votes 222 39.02%
Dominari	N/A	N/A

Summary

Dominari beats Minerva Neurosciences on 9 of the 13 factors compared between the two stocks.